DDrare: Database of Drug Development for Rare Diseases

266. 家族性地中海熱
［臨床試験数：27，薬物数：23（DrugBank：6），標的遺伝子数：14，標的パスウェイ数：57］

Searched query = "Familial mediterranean fever"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 0.9% physiological saline; ACZ885; ACZ885, 150mg/1.0ml; CANAKINUMAB; Canakinumab; Colchicine; Colchicine sprinkle capsules; Diagnostic Test: colchicine level measurement; IL-1 Trap; INN-Tocilizumab; Ilaris; Kineret; One additional blood sample during a planned blood test; Other: Colchicine Cessation; Other: Wheat flour; Probiotic; Rilonacept; RoActemra; RoActemra® 20mg/ml Konzentrat; TOCILIZUMAB; Tocilizumab; Tocilizumab Infusion RoAcemtra (EU); Wheat

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03446209 (ClinicalTrials.gov)	April 23, 2018	11/12/2017	Tocilizumab for the Treatment of Familial Mediterranean Fever	Tocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept Study	Familial Mediterranean Fever	Drug: Tocilizumab Infusion RoAcemtra (EU);Drug: 0.9% physiological saline	University Hospital Tuebingen	NULL	Completed	18 Years	64 Years	All	30	Phase 2	Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03446209
(ClinicalTrials.gov)

April 23, 2018

11/12/2017

Tocilizumab for the Treatment of Familial Mediterranean Fever

Tocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept Study

Familial Mediterranean Fever

Drug: Tocilizumab Infusion RoAcemtra (EU);Drug: 0.9% physiological saline

University Hospital Tuebingen

NULL

Completed

18 Years

64 Years

All

Phase 2

Germany